Idioma:

Time trends in prevalence of p16 positivity and combined HPV/p16 positivity in a large cohort of Danish vulvar cancer patients

Rasmussen, Christina Louise ; Thomsen, Louise T. ; Baandrup, Louise ; Franzmann, Maria Benedicte ; Kjær, Alexander K. ; Larsen, Lise Grupe ; Madsen, Else Mejlgaard ; Salinas, Nadia Margeth Villena ; Schledermann, Doris ; Winberg, Birgitte Hjelm ; Ørnskov, Dorthe ; Waldstrøm, Marianne ; Kjær, Susanne K.

International journal of cancer, 2023-06, Vol.152 (11), p.2424-2432 [Periódico revisado por pares]

Hoboken, USA: John Wiley & Sons, Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Time trends in prevalence of p16 positivity and combined HPV/p16 positivity in a large cohort of Danish vulvar cancer patients
Autor: Rasmussen, Christina Louise ; Thomsen, Louise T. ; Baandrup, Louise ; Franzmann, Maria Benedicte ; Kjær, Alexander K. ; Larsen, Lise Grupe ; Madsen, Else Mejlgaard ; Salinas, Nadia Margeth Villena ; Schledermann, Doris ; Winberg, Birgitte Hjelm ; Ørnskov, Dorthe ; Waldstrøm, Marianne ; Kjær, Susanne K.
Assuntos: Cancer ; Carcinoma in Situ - pathology ; Carcinoma, Squamous Cell - pathology ; Cross-Sectional Studies ; Cyclin-Dependent Kinase Inhibitor p16 - metabolism ; Denmark - epidemiology ; DNA, Viral ; Female ; Genital cancers ; HPV ; Human papillomavirus ; Humans ; Medical research ; Morbidity ; p16 ; Papillomaviridae - genetics ; Papillomaviridae - metabolism ; Papillomavirus Infections - complications ; Papillomavirus Infections - epidemiology ; Papillomavirus Infections - pathology ; Prevalence ; Squamous cell carcinoma ; time trends ; Trends ; Tumor suppressor genes ; Tumors ; vulvar cancer ; Vulvar Neoplasms - epidemiology ; Vulvar Neoplasms - pathology
É parte de: International journal of cancer, 2023-06, Vol.152 (11), p.2424-2432
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Vulvar cancer is rare, but causes substantial morbidity in affected patients. A subset of vulvar cancers is caused by high‐risk human papillomavirus (hrHPV), which primarily exerts its oncogenic effect through upregulation of tumor suppressor protein p16. Tumors positive for both hrHPV and p16 (double positive) are assumed to be HPV‐driven, but only few large studies have investigated the combined prevalence of hrHPV and p16 positivity in vulvar cancer over time. In this Danish cross‐sectional study, we assessed the prevalence of p16 positivity and double positivity for hrHPV and p16 in a large sample of vulvar squamous cell carcinomas (VSCCs) diagnosed during 1990 to 2017. In a nationwide register, we identified VSCCs from 13 hospitals across Denmark, and collected archival tumor tissue for hrHPV testing with INNO‐LiPA and immunohistochemical p16 staining. We calculated the prevalence of hrHPV, p16 positivity and double positivity according to time, age and histological subtype and evaluated time trends through estimated annual percentage changes. We included 1278 VSCCs. Overall, 35.0% (95% confidence interval [CI]: 32.4‐37.6) were positive for p16 and 31.0% (95% CI: 28.4‐33.5) were positive for both hrHPV and p16. The prevalence of p16 positivity and double positivity increased over time, both in women aged ≤59 and ≥60 years. The double positive prevalence was higher in nonkeratinizing (60.7%) and warty/basaloid VSCCs (67.5%) than in keratinizing (16.1%) and verrucous VSCCs (5.0%). These results indicate that approximately one‐third of vulvar cancers were caused by hrHPV infection, supporting a substantial preventive potential of the HPV vaccine. What's new? A subset of vulvar cancers is caused by high‐risk human papillomavirus (HPV), which primarily exerts its oncogenic effect through upregulation of tumor suppressor protein p16. How the proportion of HPV‐driven vulvar cancers has changed over time remains largely unexplored. This Danish cross‐sectional study estimated HPV prevalence and p16 positivity in more than 1200 vulvar cancer cases diagnosed in 1990 to 2017. The proportion of HPV‐driven tumors (ie, positive for both HPV and p16) increased to 35.7% in the most recent period. The findings support the potential of HPV vaccination to substantially prevent vulvar cancer.
Editor: Hoboken, USA: John Wiley & Sons, Inc
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Time trends in prevalence of p16 positivity and combined HPV/p16 positivity in a large cohort of Danish vulvar cancer patients

Hoboken, USA: John Wiley & Sons, Inc

Buscando em bases de dados remotas. Favor aguardar.